Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis
The amyotrophic lateral sclerosis treatment market is expected to register a CAGR of 6.3% during the forecast period (2022-2027).
COVID-19 had a significant impact on the studied market as it affected not only diagnostic and treatment procedures but also research and development activities in the area. For instance, in June 2020, the World Health Organization issued the results of a survey conducted in 155 countries for three weeks in May 2020, which showed that the prevention and treatment services of various chronic diseases, including various neurodegenerative disorders, had been severely disrupted, and this has become a significant concern because people living with chronic disorders were at higher risk of severe COVID-19-related illness and death. Therefore, COVID-19 harmed the studied market.
In addition, the rising prevalence of amyotrophic lateral sclerosis and the growing geriatric population are actively affecting the growth of the studied market.
According to the United Nations World Population Prospects 2022 report, there are 77.1 million people aged 65 years or over living in the world in 2022, and this number is projected to reach 1.6 billion by the year 2050. This surge in the geriatric population is expected to increase the burden of rare neurological diseases which is likely to augment the growth of the studied market over the forecast period.
Furthermore, the article titled "Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants" published in Neuroepidemiology Journal in July 2021 stated that combined prevalence rates (per 100,000 people) and incidence rates (per 100,000 person-years) were 6.22 and 2.31 for Europe, 5.20 and 2.35 for North America, 3.41 and 1.25 for Latin America, 3.01 and 0.93 for Asian countries excluding Japan, and 7.96 and 1.76 for Japan, respectively. The increase in prevalence and incidence of the disease is expected to increase the demand for the treatment and thus boost the market growth.
The advancements and increasing product approvals, along with partnerships and collaborations by key players are helping in the market growth. For instance, in June 2021, CRISPR Therapeutics and CapsidaBiotherapeutics Inc. entered into a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies using CRISPR technology delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia. Such partnerships are likely to bolster market growth.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, the high cost of treatment is likely to impede market growth.
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends
This section covers the major market trends shaping the Amyotrophic Lateral Sclerosis Treatment Market according to our research experts:
Medications Are Expected To Witness Healthy Growth Over the Forecast Period
Medications in amyotrophic lateral sclerosis treatment are estimated to witness healthy growth as they help relieve symptoms, panic attacks, pain, and depression. Medications such as riluzole and edaravone are the only two drugs that are approved by the Food and Drug Administration (FDA) to treat amyotrophic lateral sclerosis.
According to the research article titled "Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis" published in the Journal of Neurology in April 2020, the overall crude worldwide ALS prevalence and incidence were 4.42 per 1,00,000 population and 1.59 per 1,00,000 person-years, respectively. ALS prevalence and incidence increased by age until the age of 70-79. Hence, the rising prevalence of ALS diseases worldwide will likely trigger the demand for these drugs for treatment and thereby drive segment growth.
Furthermore, the engagement of various companies in clinical trials and new drug development associated with amyotrophic lateral sclerosis treatment will boost the growth of the market segment. For instance, in April 2020, GENUV, Inc. began the Phase 1 and 2 clinical trials to evaluate the safety, tolerability, and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis and was expected to be completed by March 2022.
Therefore, there is a growth in the medication segment of the studied market over the forecast period.
North America is Expected is Expected to Dominate Amyotrophic Lateral Sclerosis Market Over the Forecast Period
North America is expected to dominate the market owing to factors such as the rising incidence of rare neurological diseases, growing geriatric population, the strong presence of industry players in the region, better healthcare infrastructure, awareness among people and healthcare industry stakeholders about available technologies, and the high concentration of market players in the United States.
The article titled "Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants" published in Neuroepidemiology journal in July 2021 stated that combined prevalence rates (per 100,000 people) and incidence rates (per 100,000 person-years) were 5.20 and 2.35 for North America. The increase in the geriatric population in the region followed by a surge in prevalence and incidence of the disease is expected to increase the demand for the treatment and thus boost the market growth in the region.
Various measures adopted by the government or healthcare organizations to spread awareness about the disease and increase research and drug development. For instance, in June 2022, the United States Food and Drug Administration (FDA) launched an action plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis (ALS). This action plan is the five-year strategy being implemented by the United States FDA for improving and extending the lives of people living with rare neurodegenerative diseases across the country. The major focus of this plan is on advancing the development of safe and effective medical products and providing complete access to novel treatments to all patients. Such initiatives are likely to augment the market growth in the region.
Therefore, owing to the above-mentioned factors, the growth of the studied market is anticipated in the North America Region.
Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Overview
The amyotrophic lateral sclerosis treatment market is slightly fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some companies are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and F.Hoffmann-La Roche AG.
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Leaders
-
Mitsubishi Tanabe Pharma Corporation
-
CORESTEM, Inc
-
BrainStorm Cell Limited
-
Amylyx Pharmaceuticals Inc.
-
Biogen
*Disclaimer: Major Players sorted in no particular order
Amyotrophic Lateral Sclerosis (ALS) Treatment Market News
- In June 2022, Canada approved Amylyx Pharmaceuticals Inc.'s new drug ALBRIOZA (also known as AMX0035) for amyotrophic lateral sclerosis.
- In May 2022, Mitsubishi Tanabe Pharma America received the United States Food and Drug Administration Approval for RADICAVA ORS (edaravone) for the Treatment of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Amyotrophic Lateral Sclerosis
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Treatment Type
5.1.1 Medication
5.1.2 Others
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Mitsubishi Tanabe Pharma Corporation
6.1.2 Sun Pharmaceutical Industries Ltd.
6.1.3 CORESTEM, Inc
6.1.4 BrainStorm Cell Limited
6.1.5 Amylyx Pharmaceuticals Inc.
6.1.6 AB Science
6.1.7 Ionis Pharmaceuticals
6.1.8 Biohaven Pharmaceutical
6.1.9 Biogen
6.1.10 CRISPR Therapeutics
6.1.11 AbbVie Inc.
6.1.12 Boehringer Ingelheim International GmbH
6.1.13 Otsuka Pharmaceutical Co., Ltd.
6.1.14 ANNEXON, INC.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Segmentation
As per the scope of the report, amyotrophic lateral sclerosis (ALS) is a neurological disorder and fatal disease that affects nerve cells in the neuron and spinal control which controls voluntary muscle movement in the human body. This disorder affects neurons which results in blockage of messages between muscles and the brain. The amyotrophic lateral sclerosis treatment market is segmented by Treatment Type (Medication and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Treatment Type | |
| Medication | |
| Others |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research FAQs
What is the current Global Amyotrophic Lateral Sclerosis Treatment Market size?
The Global Amyotrophic Lateral Sclerosis Treatment Market is projected to register a CAGR of 6.30% during the forecast period (2024-2029)
Who are the key players in Global Amyotrophic Lateral Sclerosis Treatment Market?
Mitsubishi Tanabe Pharma Corporation, CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc. and Biogen are the major companies operating in the Global Amyotrophic Lateral Sclerosis Treatment Market.
Which is the fastest growing region in Global Amyotrophic Lateral Sclerosis Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Amyotrophic Lateral Sclerosis Treatment Market?
In 2024, the North America accounts for the largest market share in Global Amyotrophic Lateral Sclerosis Treatment Market.
What years does this Global Amyotrophic Lateral Sclerosis Treatment Market cover?
The report covers the Global Amyotrophic Lateral Sclerosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Amyotrophic Lateral Sclerosis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Amyotrophic Lateral Sclerosis Treatment Industry Report
The report on the Amyotrophic Lateral Sclerosis (ALS) market provides an in-depth industry analysis, focusing on various treatment types such as medication and others. The market is segmented by distribution channels including hospital pharmacies, retail pharmacies, and others, and covers geographical regions like North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
The industry report highlights the market trends and market growth, offering a detailed market forecast and market overview. It also includes an industry outlook and industry trends, presenting valuable market data and industry statistics. The report example and report PDF provide a comprehensive review of market segmentation and market value.
Furthermore, the industry research delves into market predictions and market review, identifying market leaders and market outlook. The report also features insights into industry sales and industry size, supported by industry information and market analysis. The report underscores the importance of market research and industry reports, offering a thorough industry overview and market forecast.
In summary, the ALS market report is an essential resource for understanding the industry's growth rate, market leaders, and market trends. It provides a clear picture of market segmentation and market value, supported by detailed industry analysis and market data. The report is an invaluable tool for research companies seeking to gain a deeper understanding of the ALS market, offering a comprehensive market review and industry outlook.
Amyotrophic Lateral Sclerosis Treatment Market Report Snapshots
